A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2D
Conditions : Obesity; Type 2 Diabetes Interventions : Drug: GUB-UCN2; Drug: Placebo Sponsors : Gubra A/S Not yet recruiting
Read the full article2d agoen
You might also wanna read
Preadmission GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Use and Early Outcomes After Pneumonia Hospitalization in Adults With Type 2 Diabetes
clinicaltrials.gov·just now
FDA approves first-of-its-kind cholesterol pill
masslive·1h ago
STAT+: Fresh turmoil roils American Diabetes Association following controversy at conference
STAT·1h ago
Lab study finds sweetener isosteviol slows growth of key gut bacteria, especially when combined with antidepressant
the-microbiologist.com·2h agoBrain Implants Are Physically Rewiring Damaged Spines
yesilscience.com·2h ago
Predicting biotech clinical trials & a new Alzheimer’s drug controversy
STAT·3h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.